161Tb-NYM032
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 161Tb-NYM032, covering 2025-02-14 to 2025-02-14. Get the full timeline:
Most recent: Clinical Trial Update: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]